What is Zevra Therapeutics, Inc.'s D&A?

Zevra Therapeutics, Inc. (ZVRA) reported D&A of $368K in Q1 2026.

How has Zevra Therapeutics, Inc.'s D&A changed year-over-year?

Zevra Therapeutics, Inc.'s D&A decreased by 77.7% year-over-year, from $1.65M to $368K.

What is the long-term trend for Zevra Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s D&A has grown at a 99.3% compound annual growth rate (CAGR), from $257K to $4.05M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Zevra Therapeutics, Inc. ZVRA D&A

D&A at other companies

BioMarin PharmaceuticalsBMRN

$16.41M-25.6%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

XER

Xeris Biopharma Holdings, Inc.XERS

$337K+7.0%

Eton Pharmaceuticals, Inc.ETON

$1.13M+11.6%

Theravance BiopharmaTBPH

$381K-7.7%

Relay Therapeutics, Inc.RLAY

$504K-58.3%

Segments

By segment

See full

Reportable Segment$368K-77.7%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+56.4%

Enterprise value$678.78M+30.8%

P/E6.2×—

P/S6.3×-5.9×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s D&A?: Zevra Therapeutics, Inc. (ZVRA) reported D&A of $368K in Q1 2026.
How has Zevra Therapeutics, Inc.'s D&A changed year-over-year?: Zevra Therapeutics, Inc.'s D&A decreased by 77.7% year-over-year, from $1.65M to $368K.
What is the long-term trend for Zevra Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s D&A has grown at a 99.3% compound annual growth rate (CAGR), from $257K to $4.05M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.